Orexigen Therapeutics (OREX) Tops Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Orexigen Therapeutics (OREX) Remains Outperform Rated at Wells Fargo
November 10, 2014 3:26 PM ESTWells Fargo maintained an Outperform rating on Orexigen Therapeutics (NASDAQ: OREX) with a price target of $9.50-$10.50. Earlier it reported Q3 results.
In the view of analyst Matthew J. Andrews, there were a number of signals that suggest early launch of... More
